Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lowell Anthony

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Orphanet Journal of Rare Diseases|November 23, 2019
Biliary tract large cell neuroendocrine carcinoma: current evidenceRiva Raiker, Aman Chauhan, Hassan Hasanein, et al.
Frontiers in Oncology|May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumorsAman Chauhan, Elise C Kohn, S Percy Ivy, et al.
Endocrine-Related Cancer|July 19, 2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II studyLarry K Kvols, Kjell E Oberg, Thomas M O'Dorisio, et al.
Theranostics|June 28, 2012
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 PentetreotideEbrahim S Delpassand, Amin Samarghandi, Jennifer Sims Mourtada, et al.
The Journal of Supportive Oncology|June 30, 2006
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trialStephen H Rosenoff, Nashat Y Gabrail, Richard Conklin, et al.
Cells|June 2, 2021
PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine TumorsZeta Chow, Jeremy Johnson, Aman Chauhan, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|January 26, 2019
Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown PrimaryAman Chauhan, Zainab Farooqui, Scott R Silva, et al.
Cancer Letters|May 27, 2024
Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumorZeta Chow, Jeremy Johnson, Aman Chauhan, et al.
Carcinogenesis|January 29, 2013
Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumorsJi Tae Kim, Jing Li, Eun Ryoung Jang, et al.
Anticancer Research|July 5, 2018
Neoadjuvant <i>Nab</i>-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOXShawn L Peterson, Muhammad Husnain, Terri Pollack, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Orphanet Journal of Rare Diseases|November 23, 2019
Biliary tract large cell neuroendocrine carcinoma: current evidenceRiva Raiker, Aman Chauhan, Hassan Hasanein, et al.
Frontiers in Oncology|May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumorsAman Chauhan, Elise C Kohn, S Percy Ivy, et al.
Endocrine-Related Cancer|July 19, 2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II studyLarry K Kvols, Kjell E Oberg, Thomas M O'Dorisio, et al.
Theranostics|June 28, 2012
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 PentetreotideEbrahim S Delpassand, Amin Samarghandi, Jennifer Sims Mourtada, et al.
The Journal of Supportive Oncology|June 30, 2006
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trialStephen H Rosenoff, Nashat Y Gabrail, Richard Conklin, et al.
Cells|June 2, 2021
PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine TumorsZeta Chow, Jeremy Johnson, Aman Chauhan, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|January 26, 2019
Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown PrimaryAman Chauhan, Zainab Farooqui, Scott R Silva, et al.
Cancer Letters|May 27, 2024
Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumorZeta Chow, Jeremy Johnson, Aman Chauhan, et al.
Carcinogenesis|January 29, 2013
Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumorsJi Tae Kim, Jing Li, Eun Ryoung Jang, et al.
Anticancer Research|July 5, 2018
Neoadjuvant <i>Nab</i>-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOXShawn L Peterson, Muhammad Husnain, Terri Pollack, et al.
Pageof 5